Kezar Life Sciences, Inc. (KZR)
7.29
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
Kezar Life Sciences Research and Development Expense (Quarterly) : 1.545M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 1.545M |
| December 31, 2025 | 5.079M |
| September 30, 2025 | 6.914M |
| June 30, 2025 | 9.583M |
| March 31, 2025 | 12.18M |
| December 31, 2024 | 16.03M |
| September 30, 2024 | 16.24M |
| June 30, 2024 | 16.30M |
| March 31, 2024 | 17.17M |
| December 31, 2023 | 22.64M |
| September 30, 2023 | 23.74M |
| June 30, 2023 | 21.00M |
| March 31, 2023 | 18.40M |
| December 31, 2022 | 14.86M |
| September 30, 2022 | 13.86M |
| June 30, 2022 | 11.35M |
| March 31, 2022 | 11.02M |
| December 31, 2021 | 9.519M |
| September 30, 2021 | 10.64M |
| Date | Value |
|---|---|
| June 30, 2021 | 9.341M |
| March 31, 2021 | 9.286M |
| December 31, 2020 | 8.117M |
| September 30, 2020 | 8.259M |
| June 30, 2020 | 7.148M |
| March 31, 2020 | 7.457M |
| December 31, 2019 | 7.431M |
| September 30, 2019 | 7.08M |
| June 30, 2019 | 6.925M |
| March 31, 2019 | 5.927M |
| December 31, 2018 | 4.673M |
| September 30, 2018 | 4.664M |
| June 30, 2018 | 5.228M |
| March 31, 2018 | 3.572M |
| December 31, 2017 | 1.636M |
| September 30, 2017 | 1.557M |
| June 30, 2017 | 1.445M |
| March 31, 2017 | 1.831M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 0.917M |
| Summit Therapeutics, Inc. | 157.73M |
| Protara Therapeutics, Inc. | 16.88M |
| Clene, Inc. | 3.135M |